IMR Press / FBL / Volume 23 / Issue 7 / DOI: 10.2741/4643

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Dissection of prodromal Alzheimer’s disease

Can Sheng1,2Yue Huang3Ying Han1,4,5,6,7,*
Show Less
1 Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, China
2 Department of Neurology, the First Hospital of Tsinghua University, Beijing, China
3 School of Medical Sciences, Faculty of Medicine, UNSW Australia, New South Wales, Australia
4 Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing,  China
5 National Clinical Research Center for Geriatric Disorders, Beijing, China
6 Beijing Institute of Geriatrics, Beijing, China
7 PKU Care Rehabilitation Hospital, Beijing, China
Front. Biosci. (Landmark Ed) 2018, 23(7), 1272–1291; https://doi.org/10.2741/4643
Published: 1 January 2018
(This article belongs to the Special Issue Precision neurology)
Abstract

Pathophysiological changes of Alzheimer’s Disease (AD) begin decades before clinical symptoms become apparent, providing an important window for early diagnosis and intervention. Prodromal stage of AD, a great opportunity for effective treatment and postponing the disease onset, has drawn extensive attention. The application of different biomarkers including neuroimaging, biochemical substances and genes makes AD-related pathology detectable in vivo and exploring novel biomarkers with relatively non-invasive and low cost has intrigued a wide range of interests. To identify individuals with high risk of conversion to AD and apply the research concept of prodromal AD into clinical practice, the utility of various biomarkers for distinguishing prodromal AD is evaluated in this review. Additionally, clinical management focusing on the stage of prodromal AD is summarized in this review for dementia prevention.

Keywords
Alzheimer’s disease
Prodromal
Biomarkers
Neuroimaging
Cerebrospinal Fluid
Support Vector Machine
Clinical Management
Review
Share
Back to top